Skip to main content
S&P 5007,376.86+0.31%DOW51,285.73-0.46%NASDAQ24,579.42+1.09%BTC$75,946.00-0.25%ETH$2,243.57+0.21%GOLD$4,079.50-0.83%OIL$90.34-0.20%
Smart Investors Daily
SID Premium
VR

NASDAQ · VRAX

Virax Biolabs Group Limited

Healthcare · Biotechnology

$0.79

Down-$0.39 (-32.89%)

Updated Nov 9, 2026, 2:51 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.92M
P/E ratio
-0.37
Dividend yield
0.00%
52-week range
$0.10 – $13.19
Volume
1.1M
Avg. volume
5.08M

Price performance · VRAX

VRAX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 6, 2026

VRAX closed at $0.79 after 20 trading sessions, down 57.19% for the selected period.

Last close
$0.79
Period change
-57.19%
Period low
$0.79
Period high
$1.85
Daily close
View OHLC price history
VRAX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 6, 2026$0.97$0.9899$0.63$0.79191.1M
Nov 5, 2026$1.33$1.3492$1.01$1.183.71M
Nov 4, 2026$1.16$1.57$1.11$1.2010.98M
Nov 3, 2026$1.09$1.175$1.04$1.0633.72K
Nov 2, 2026$1.17$1.18$1.10$1.1025.61K
Oct 30, 2026$1.285$1.30$1.18$1.2123.67K
Oct 29, 2026$1.30$1.33$1.235$1.3258.27K
Oct 28, 2026$1.17$1.21$1.16$1.2010.07K
Oct 27, 2026$1.23$1.23$1.14$1.1911.93K
Oct 26, 2026$1.26$1.26$1.18$1.1910.47K
Oct 23, 2026$1.24$1.2651$1.20$1.2233.98K
Oct 22, 2026$1.29$1.39$1.15$1.23538.26K
Oct 21, 2026$1.42$1.49$1.32$1.3414.71K
Oct 20, 2026$1.50$1.50$1.35$1.3714.06K
Oct 19, 2026$1.50$1.6478$1.38$1.4012.09K
Oct 16, 2026$1.62$1.64$1.38$1.4540.63K
Oct 15, 2026$1.66$1.76$1.55$1.620244.19K
Oct 14, 2026$1.77$1.78$1.61$1.6538.75K
Oct 13, 2026$1.80$1.86$1.7201$1.738143.75K
Oct 12, 2026$1.81$1.8999$1.78$1.8571.26K

Latest VRAX news

The latest Smart Investors Daily articles mentioning VRAX.

Stock researchCompany · Overview

VRAX research

Overview

Company profile and research snapshot.

Company profile

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
VRAX recent ratings
DateFirmRatingTarget
Jan 9, 2026HC Wainwright & Co.Buy—
Mar 31, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. for its ImmuneSelect research-use immune profiling products.

Benzinga · Oct 19, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved upwards by

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By